Background In a previous randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in patients with acute respiratory distress syndrome (ARDS) reduced extravascular lung water and plateau airway pressure. We assessed the eff ects of this intervention on mortality in patients with ARDS.
Introduction
Acute respiratory distress syndrome (ARDS) occurs in about 14% of mechanically ventilated patients, and causes a mortality of 40-60%
1-3 and a substantial reduction in survivors' quality of life. [4] [5] [6] β-2 agonists could be a potential pharma cological intervention because they act on the many pulmonary cellular pathways thought to be associated with the pathophysiology of ARDS. These drugs reduce neutrophil sequestration, activation, and production of infl ammatory cytokines, 7, 8 and activate β-2 receptors on alveolar type-1 and type-2 cells, which increases intracellular cyclic adenosine monophosphate, leading to increased sodium transport and acceleration of alveolar fl uid reabsorption. [9] [10] [11] In patients with ARDS given salbutamol, we reported invivo evidence of reduced permeability of alveolar capillaries, and in-vitro evidence of enhanced wound repair in epithelial monolayers. 12 These data suggest that β-2 agonists could maintain alveolar-capillary integrity, thereby reducing alveolar fl ooding.
Findings from the β-agonist lung injury trial (BALTI) 13 -a single-centre, randomised controlled trial in 40 patients with ARDS-showed that an infusion of salbutamol for 7 days caused signifi cant reductions in extravascular lung water and plateau airway pressure. However, this trial was not designed to assess the potential eff ects on mortality. We therefore assessed whether treatment with salbutamol in the early course of ARDS would improve clinical outcomes.
Methods

Study design and participants
We undertook a multicentre, pragmatic, double-blind, placebo-controlled, parallel-group, randomised trial at 46 UK intensive-care units between December, 2006, and March, 2010. Eligible participants were intubated and mechanically ventilated adults aged 16 years and older within 72 h of ARDS onset. Patients were identifi ed and recruited by local investigators at each site. We defi ned ARDS in accordance with the American European Consensus criteria: 14 a pressure of arterial oxygen to fractional inspired oxygen concentration (PaO 2 /F I O 2 ) ratio of 200 mm Hg or less, bilateral pulmonary infi ltrates consistent with oedema, and the absence of clinically evident left atrial hypertension. Exclusion criteria were pregnancy; current treatment with intravenous β-2 agonist or need for continuous, regular, aerolised β-2 agonists; current treatment with β-adrenergic antagonists; imminent withdrawal of medical treatment; chronic liver disease, defi ned as Child-Pugh grade C; and enrolment in another clinical trial of an investigational medicinal product within the previous 28 days.
Sedated patients did not have capacity to give consent; therefore, consistent with requirements of the EU clinical trial directive, 15 we obtained written informed consent from a personal or professional legal representative before randomisation. All surviving patients were informed about the trial at the earliest opportunity after regaining competence and consent to continue in the trial was sought. The study protocol 16 was approved for all centres by the Oxfordshire Research Ethics Committee A. Site specifi c approval was obtained at each site. The trial was monitored for safety by an independent Data Monitoring and Ethics Committee.
Randomisation and masking
Study drug packs were prepared by Bilcare Global Clinical Supplies (Europe; Powys, UK). The active and placebo drug components of the infusions were packaged identically into numbered treatment packs, each containing 5 mL of either salbutamol sulphate BP (1 mg/mL in a sterile isotonic solution, GlaxoSmithKline, Middlesex, UK) or placebo (0·9% sterile sodium chloride). We used a computer-generated randomisation sequence with a block size of eight. Patients were randomly assigned in a 1:1 ratio by a centralised 24 h telephone or web-based randomisation service (Uni versity of Aberdeen, UK). Randomisation was minimised by centre, PaO 2 /F I O 2 ratio (≤50, 51-99, or ≥100 mm Hg), and age (<64, 65-84, ≥85 years). Participants, care providers, and investigators were masked to group assignment.
Procedures
We obtained acute physiology and chronic health evaluation II (APACHE II) scores from Intensive Care National Audit and Research Centre (ICNARC) for sites (n=36) that participate in the ICNARC's Case Mix Programme or, for non-participating sites (ten), we obtained data necessary for calculation of the scores. We used the APACHE II score to calculate the mortality risk, which we used for subgroup analysis.
The most likely cause of ARDS was identifi ed by the treating clinician and categorised as direct lung injury (smoke or toxin inhalation, aspiration of gastric content, near drowning, thoracic trauma, pneumonia, or other) or indirect lung injury (sepsis, cardiopulmonary bypass, pancreatitis, non-thoracic trauma, other). The protocol recommended use of a lung protective ventilation strategy on the basis of ideal bodyweight, 17 fl uid restriction, 18 and appropriate high positive end-expiratory pressure.
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Compliance with recommendations for protective ventilation were assessed at baseline only (tidal volumes per kg ideal bodyweight). All other treatments were delivered in accordance with local clinical practice. Before the start of recruitment, the intensive-care unit nurse was trained to monitor side-eff ects of the treatment and to inform the research team as necessary. Infusion syringes were prepared immediately before use by the nurse and contained two ampoules of the blinded solutions (salbutamol or placebo) diluted with 40 mL of saline in a 50 mL syringe. Salbutamol and placebo were administered through a dedicated intravenous line at a rate of 0•075 mL/kg ideal bodyweight per h (equivalent to 15 μg salbutamol per kg ideal bodyweight per h). The patient was measured from heel to vertex with a soft tape measure, and the ideal bodyweight and infusion rate obtained from the conversion table. 17 If any patient developed a tachycardia (heat rate >140 beats per min), new arrhythmia, or lactic acidosis, we adjusted the infusion rate according to a prespecifi ed dose-adjustment schedule. 15 Infusion of the study drug was stopped at 7 days, or earlier if clinically indicated.
Study outcomes
The primary outcome was 28-day mortality, defi ned as death up to the end of calendar day 28 after random isation. Secondary outcomes were mortality in the intensive-care unit or hospital before fi rst discharge; ventilator-free and organ failure-free days from randomisation to day 28; length of stay in intensive-care unit and hospital; and tachycardia, new arrhythmia, or other side-eff ects suffi cient to stop treatment with trial drug. We defi ned ventilator-free days as the number of calendar days after patients started unassisted breathing until day 28 after randomisation for patients who survived at least 48 consecutive hours after start of unassisted breathing. 20 The number of ventilator-free days was zero for patients who died without start of unassisted breathing or before 48 consecutive hours of unassisted breathing. 20 We defi ned organ failure-free days as the number of days in the fi rst 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defi ned by the Critical Care Minimum Dataset. 21 We did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation. We requested causes of death as recorded on the death certifi cate for the disorder directly leading to death. Patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward, or until day 28.
Statistical analysis
We based the sample-size calculation on our BALTI trial 13 and on 2005 data from the Intensive Care National Audit and Research Centre. The target sample size of 1334 gave 90% power at p<0•05 to detect a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%. We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee. The committee used the Haybittle-Peto 22 stopping guideline: a diff erence of three standard errors would be needed before considering recommending trial cess ation for benefi t at an interim analysis.
All analyses were based on intention-to-treat analyses. We compared the primary outcome and other dichot omous outcomes using RRs and 95% CIs. We compared continuous outcomes with mean diff erences and their 95% CIs. We analysed 28-day mortality with survival analysis, and by comparison of the two groups with hazard ratios and 95% CIs and the Kaplan-Meier curve. All reported p values are two-sided and were not adjusted for multiple comparisons. We used prespecifi ed sub group analyses to investigate the eff ects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the eff ect of salbutamol. All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models. We did a post-hoc analysis for the main causes of death as recorded on the death certifi cates of participants who died within 28 days of randomisation. This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. FGS, SG, GDP, and SEL had full access to all the data in the study, and the corresponding author had fi nal responsibility for the decision to submit for publication. 
Results
46 study sites participated in recruitment; a further 25 sites obtained approval to start the trial, but were unable to do so before recruitment was stopped. Recruitment was stopped after the second interim analysis, when the Data Monitoring and Ethics Committee reviewed the results for 273 patients in March, 2010. The RR for the primary outcome at this time was 1•55 (95% CI 1•07-2•24). Therefore, the committee recommended suspension of recruitment to BALTI-2 because of a signifi cant (p=0•02) adverse eff ect of salbutamol on 28-day mortality, and the 99•8% CI excluded a benefi t for salbutamol of the size anticipated in the protocol. Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time. The trial steering committee endorsed this recommendation and closed recruitment on March 23, 2010 . Figure 1 shows the trial profi le. 326 patients were randomly assigned to receive either salbutamol or placebo. Two patients withdrew consent; no outcome data were available for these patients. The study drug was not given to two patients in the salbutamol group: one patient needed a β blocker between randomisation and starting the drug, the other patient's next of kin refused to have a separate intravenous line inserted for infusion after initially giving consent.
Both groups had similar baseline characteristics (table 1) . The median time from randomisation to start of the study infusion was similar in both groups (salbutamol 1 . The risks of patients developing a tachycardia, new arrhythmia, or lactic acidosis severe enough to warrant stopping of the study drug were substantially higher in the salbutamol group than in the placebo group (table 2) .
More patients died 28 days after randomisation in the salbutamol group than in the placebo group (RR 1•47, 95% CI 1•03-2•08; p=0•03; table 2). Survival analysis of the primary outcome (fi gure 3) showed a hazard ratio of 1·56 (95% CI 1·03-2·36). Salbutamol resulted in a 10•9% (95% CI 1•0-20•4) absolute increase in 28-day mortality (table 2). One additional death occurred for every 9•2 (95% CI 4•9-100•9) patients with ARDS given salbutamol. The number of deaths before discharge from either intensive-care unit or hospital did not diff er signifi cantly between groups (p=0·10 and p=0·26, respectively; table 2). We noted an 8•4% (95% CI -1•7 to 18•3) absolute increase in intensive-care unit mortality and a 6•0% (-4•4 to 16•2) increase in hospital mortality in the salbutamol group (table 2) .
Ventilator-free and organ failure-free days in the fi rst 28 days after randomisation were both reduced in the salbutamol group (table 2) . We detected no clear diff erences between the groups in length of stay in intensive-care units and hospitals (table 2) . Surviving patients with ARDS in the salbutamol group needed a mean of 3•4 more days (95% CI -0·3 to 7·1) in intensive-care units than did those in the placebo group (table 2) . Serious adverse events (other than those recorded as trial outcomes, eg, death) were reported for 13 participants (nine in salbutamol group, four in placebo group). Four of these events were The analysis suggested weak evidence of a possible interaction eff ect with age. However, the eff ect was small and strongly aff ected by the oldest age stratum (>85 years), in which there were only four patients; therefore, this fi nding is likely to be due to chance.
Adjustment for baseline variables (age, sex, PaO 2 /F I O 2 ratio, and cause) alone or in combination made no substantial diff erence to the estimate of the treatment eff ect of salbutamol or its statistical signifi cance (data not shown). We obtained data for cause of death for 91 of 93 patients who died by day 28 (55/55 in the salbutamol group, 36/38 in the placebo group). Because of the diversity of individual diagnoses, we grouped results for cause of death according to organ system. Diagnoses for the respiratory system were the most common primary cause of death in both groups (28 [51%] patients given salbutamol vs 20 [53%] given placebo), followed by multiorgan failure (12 [22%] vs 14 [37%]). ARDS was recorded on the death certifi cate for 11 (21%) patients in the salbutamol group, and eight (21%) in the placebo group.
Discussion
Our fi ndings show that intravenous salbutamol given to patients with early ARDS signifi cantly increased 28-day mortality, and reduced ventilator-free days and organ failure-free days compared with those given placebo. Treatment was poorly tolerated because of tachycardia, arrhythmias, and lactic acidosis. These fi ndings were unexpected; however, they have clarifi ed whether intravenous infusion of β-2 agonists should be used in patients with ARDS (panel). The ALTA trial 23 of aerolised salbutamol for treatment of acute lung injury in 282 patients was stopped because the primary endpoint, ventilator-free days, had crossed predefi ned futility boundaries, making the probability of a positive trial very low. Nevertheless, in that trial, clinical outcomes were worse in the salbutamol group than in the placebo group, particularly in the most severely ill patients. Because we recruited a large number of ARDS patients, with characteristics similar to other multicentre trials, 2,23 from 46 multidisciplinary intensive-care units in the UK, our data could be generalised to other intensive-care units.
Our trial has some limitations. First, mortality in the placebo group was much lower than anticipated. This outcome could have been caused by changes in the mortality of ARDS because of improvements in treatments. 24 Second, because of the nature of pragmatic trials, we did not obtain prospective data for cardiovascular comorbidity and causes of deaths, including results of post-mortem. These data could provide useful infor mation about possible explanations of these unexpected trial results. Third, the trial was stopped at a smaller sample size than was planned; therefore, the precision of the treatment eff ect estimates is lower than expected. A large sample size and narrow CIs might clarify salbutamol's eff ects on secondary outcomes, such as mortality rates in intensive-care units and hospitals. Fourth, although we recommended best practice for ARDS (protective ventilation, conservative fl uid management), we did not measure details of clinical management. We selected the dose of salbutamol (15 μg/kg ideal bodyweight per h) after an early dose-ranging study identifi ed it to be the maximum dose that critically ill patients could receive without an increase in ventricular, atrial tachycardia, or ectopy. This dose was used in the BALTI study 25 and resulted in steadystate plasma concen trations of salbutamol (1×10-⁶ M), and is associated with a 100% increase in clearance of basal alveolar fl uid in animal studies of ARDS. The dose is at the high end of the manufacturer's recommended dosing regimen; as such, a benefi cial eff ect of salbutamol could have been outweighed by its adverse eff ects at this dose. A lower dose of salbutamol might have produced a diff erent outcome, so the conclusions from our study can relate only to the dose given.
Panel: Research in context
Systematic review
We searched PubMed and The Cochrane Library from Jan 1, 1960, to Aug 31, 2011, for randomised controlled trials or systematic reviews investigating the use of β agonists for the treatment of patients with established acute respiratory distress syndrome (ARDS). We used a combination of text ("salbutamol", "beta agonist", "ARDS") and medical subject headings terms ("adrenergic beta-agonists", "respiratory distress syndrome", "adult"). We identifi ed two randomised controlled trials 13, 23 and no systematic reviews. Both trials were at low risk of bias, according to the criteria of the Cochrane risk of bias method.
The β-agonist lung injury trial (BALTI) 13 recruited 40 patients and used an intravenous infusion of salbutamol. Findings from the trial showed reductions in extravascular lung water and plateau airway pressure in the group given salbutamol, but no diff erence in 28-day mortality (11 [58%] of 19 patients died in the salbutamol group vs 14 [67%] of 21 in the placebo group). 12 The aerosolised beta-2 agonist for treatment of acute lung injury (ALTA) 23 trial randomly assigned 282 patients with acute lung injury to receive aerosolised salbutamol (5 mg) or placebo. The trial was stopped early on grounds of futility. The number of ventilator-free days (salbutamol 14·4 days vs placebo 16·6 days; 95% CI for the diff erence -4·7 to 0·3 days; p=0·087) or hospital mortality (35 [23%] of 152 patients died in the salbutamol group vs 23 [17%] of 130 in the placebo group; 95% CI for the diff erence -4·0 to 14·7; p=0·30) did not diff er signifi cantly.
Interpretation
The eff ects on ventilator-free days and mortality in ALTA were consistent with those in BALTI-2, but our trial shows clearly that intravenous administration of salbutamol at 15 μg/kg ideal bodyweight per h to patients with early ARDS was poorly tolerated, is unlikely to be benefi cial, and could worsen outcomes. Routine use of β-2 agonist therapy in mechanically ventilated patients with ARDS cannot be recommended. Confl icts of interest FGS and GDP have received an investigator-led research grant from GlaxoSmithKline. GDP and DFM have consulted for, sat on advisory boards for, and received lecture fees from GlaxoSmithKline, and have received lecture fees from AstraZeneca for educational meetings (all unrelated to β agonists). All other authors declare that they have no confl icts of interest.
The mechanisms underlying the increased mortality in the salbutamol group remain unclear. That the survival curves for salbutamol and placebo seem to continue to diverge after the end of the salbutamol infusion might be notable, so the mechanism could be complex. The ALTA investigators 23 explored possible explanations for the scarcity of eff ect of β-2 agonists, including poor drug delivery to injured and oedematous alveoli, inadequate alveolar epithelial response, downregulation of β-2 receptors, and genetic variation. Adverse eff ects on the cardiovascular system-eg, tachyarrythmias, cardiomyopathy and myocardial infarction-could have been harmful. 26, 27 Recruitment of damaged alveoli 28 and activation of the renin-angiotensin aldosterone system could adversely aff ect pulmonary fl uid balance. 29 Findings from this multicentre trial provide evidence that intravenous salbutamol in the early course of ARDS was poorly tolerated, is unlikely to be benefi cial, and could worsen outcomes. Routine use of β-2 agonist therapy in mechanically ventilated patients with ARDS cannot be recommended.
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